CDKN2A mutation and deletion status in thin and thick primary melanoma

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3511-3515

  Cachia, A R ^a   Indsto, J O ^a   McLaren, K M ^a   Mann, G J ^a   Arends, M J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CHROMOSOME 18P; CHROMOSOME 9P; CHROMOSOME BREAKAGE; DISEASE MARKER; GENE DELETION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; SOMATIC MUTATION; TISSUE SLICE; TUMOR SUPPRESSOR GENE;

CHROMOSOMES, HUMAN, PAIR 9; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P16; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SKIN NEOPLASMS;

EID: 0033818626     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Homozygous deletions within human chromosome band 9p21 in melanoma
2. A cell cycle regulator potentially involved in genesis of many tumor types
3. Chromosome 9 deletion in sporadic and familial melanomas in vivo
4. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines [published erratum appears in Oncogene, 11: 2455, 1995]
5. Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions
6. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22
7. Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma
8. Mutations associated with familial melanoma impair p16(INK4) function
9. Link to hereditary melanoma brightens mood for p16 gene
10. Tumourderived p16 alleles encoding proteins defective in cell-cycle inhibition
11. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16
12. p16 Proteins from melanoma-prone families are deficient in binding to Cdk4
13. Involvement of CDKN2 (p16(INK4A)/MTS1) and p15(INK4B)/MTS2 in human leukemias and lymphomas
14. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
15. Germline p16(INK4A) mutation and protein dysfunction in a family with inherited melanoma
16. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia
17. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
18. Cell-cycle regulators and cancer
19. A novel p16(INK4A) transcript
20. A new type of p16(INK4)/MTS1 gene transcript expressed in B-cell malignancies
21. Complex structure and regulation of the p16 (MTS1) locus
22. p19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
23. Mutations in the CDKN2A (p16(INK4a) gene in microdissected sporadic primary melanomas
24. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
25. Infrequent mutation of p16(INK4) in sporadic melanoma
26. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression
27. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma
28. Malignant tumors (melanomas and related lesions): Tumor progression phases and classification
29. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma
30. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma
31. Loss of the p16(INK4a) and p15(INK4b) genes, as well as neighboring 9p21 markers, in sporadic melanoma
32. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma
33. p16INK4 mutations and altered expression in human tumors and cell lines
34. CDKN2A (p16INK4A) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas
35. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma
36. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology
37. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
38. Homozygous deletion of the p16(INK4a) and the p15(INK4b) tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma
39. p16(INK4a) inactivation is not frequent in uncultured sporadic primary cutaneous melanoma
40. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds
41. Mutation of the CDKN2A 5'UTR creates an aberrant initiation codon and predisposes to melanoma
42. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
43. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
44. Evidence for U.V. induction of CDKN2 mutations in melanoma cell lines
45. Loss of heterozygosity at chromosome 9p21 (INK4-p14(ARF) locus): Homozygous deletions and mutations in the p16 and p14(ARF) genes in sporadic primary melanomas